Therapeutic Developments for Tics and Myoclonus

Movement Disorders

Volumn 30, Issue 11, 2015, Pages 1566-1573

  Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Myoclonus; Tics; Tourette syndrome; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; BOTULINUM TOXIN; CLONAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; SEROTONIN AGONIST; NEUROTOXIN;

ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CLINICAL FEATURE; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DISABILITY; HUMAN; HYPERKINESIA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MYOCLONUS; OBSESSIVE COMPULSIVE DISORDER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TIC; TREATMENT INDICATION; TREATMENT OUTCOME; BRAIN DEPTH STIMULATION; PROCEDURES; TICS;

BOTULINUM TOXINS; DEEP BRAIN STIMULATION; HUMANS; MYOCLONUS; NEUROTOXINS; TICS;

EID: 84941599668     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26414     Document Type: Review

References (53)

1. Gilbert DL, Jankovic J. Pharmacological treatment of Tourette syndrome. JOCRD 2014;3:407-414.
2. Hirschtritt ME, Lee PC, Pauls DL, et al.; for the Tourette Syndrome Association International Consortium for Genetics. Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiatry 2015;72:325-333.
3. Hallett M. Tourette syndrome: update. Brain Dev 2015;37:651-655.
4. Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol 2014;13:100-112.
5. Mills K, Mari Z. An update and review of the treatment of myoclonus. Curr Neurol Neurosci Rep 2015;15:512.
6. Baizabal-Carvallo JF, Cardoso F, Jankovic J. Myorhythmia: phenomenology, etiology, and treatment. Mov Disord 2015;30:171-179.
7. Scahill L, Woods DW, Himle MB, et al. Current controversies on the role of behavior therapy in Tourette syndrome. Mov Disord 2013;28:1179-1183.
8. McGuire JF, Piacentini J, Brennan EA, Lewin AB, Murphy TK, Small BJ, Storch EA. A meta-analysis of behavior therapy for Tourette syndrome. J Psychiatr Res 2014;50:106-112.
9. Volkow ND, Swanson JM. Clinical practice: adult attention deficit-hyperactivity disorder. N Engl J Med 2013;369:1935-1944.
10. Feldman HM, Reiff MI. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med 2014;370:838-846.
11. Efron D. Attention-deficit/hyperactivity disorder: the past 50 years. J Paediatr Child Health 2015;51:69-73.
12. Grant JE. Clinical practice: obsessive-compulsive disorder. N Engl J Med 2014;371:646-653.
13. Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 2015;18. pii: pyv047. doi: 10.1093/ijnp/pyv047.
14. Reese HE, Scahill L, Peterson AL, et al. The premonitory urge to tic: measurement, characteristics, and correlates in older adolescents and adults. Behav Ther 2014;45:177-186.
15. Mogwitz S, Buse J, Ehrlich S, Roessner V. Clinical pharmacology of dopamine-modulating agents in Tourette's syndrome. Int Rev Neurobiol 2013;112:281-349.
16. Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord 2014;29:126-130.
17. Jankovic J, Roos RA. Chorea associated with Huntington's disease: to treat or not to treat? Mov Disord 2014;29:1414-1418.
18. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) 2013;3:tre-03-161-4138-1.
19. Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J Clin Psychiatry 2013;74:e772-e780.
20. Ryu S, Yoo JH, Kim JH, et al. Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study. J Clin Psychopharmacol 2015;35:13-21.
21. Gilbert DL, Budman CL, Singer HS, et al. A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol 2014;37:26-30.
22. Termine C, Selvini C, Rossi G, Balottin U. Emerging treatment strategies in Tourette syndrome: what's in the pipeline? Int Rev Neurobiol 2013;112:445-480.
23. Cavanna AE, Nani A. Antiepileptic drugs and Tourette syndrome. Int Rev Neurobiol 2013;112:373-389.
24. Ye L, Lippmann S. Tourette disorder treated with valproic acid. Clin Neuropharmacol 2014;37:36-37.
25. Thomas R, Cavanna AE. The pharmacology of Tourette syndrome. J Neural Transm 2013;120:689-694.
26. Kurlan RM. Treatment of Tourette syndrome. Neurotherapeutics 2014;11:161-165.
27. Pringsheim T, Hirsch L, Gardner D, Gorman DA. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry 2015;60:42-51.
28. Kluger B, Triolo P, Jones W, Jankovic J. The therapeutic potential of cannabinoids for movement disorders. Mov Disord 2015;30:313-327.
29. Müller-Vahl KR. Treatment of Tourette syndrome with cannabinoids. Behav Neurol 2013;27:119-124.
30. Persaud R, Garas G, Silva S, Stamatoglou C, Chatrath P, Patel K. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep 2013;4:10.
31. Orth M, Münchau A. Transcranial magnetic stimulation studies of sensorimotor networks in Tourette syndrome. Behav Neurol 2013;27:57-64.
32. Landeros-Weisenberger A, Mantovani A, Motlagh MG, et al. Randomized sham controlled double-blind trial of repetitive transcranial magnetic stimulation for adults with severe Tourette syndrome. Brain Stimul 2015;8:574-581.
33. Jimenez-Shahed J. Design challenges for stimulation trials of Tourette's syndrome. Lancet Neurol 2015;14:563-565.
34. Kefalopoulou Z, Zrinzo L, Jahanshahi M, et al. Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial. Lancet Neurol 2015;14:595-605.
35. Huasen B, McCreary R, Evans J, Potter G, Silverdale M. Cervical myelopathy secondary to Tourette's syndrome managed by urgent deep brain stimulation. Mov Disord 2014;29:452-453.
36. Zhang JG, Ge Y, Stead M, et al. Long-term outcome of globus pallidus internus deep brain stimulation in patients with Tourette syndrome. Mayo Clin Proc 2014;89:1506-1514.
37. Schrock LE, Mink JW, Woods DW, et al.; Tourette Syndrome Association International Deep Brain Stimulation (DBS) Database and Registry Study Group. Tourette syndrome deep brain stimulation: a review and updated recommendations. Mov Disord 2015;30:448-471.
38. Caviness JN. Treatment of myoclonus. Neurotherapeutics 2014;11:188-200.
39. Käliäinen R. Progressive myoclonus epilepsies. Semin Neurol 2015;35:293-299.
40. Hyppönen J, Äikiä M, Joensuu T, et al. Refining the phenotype of Unverricht-Lundborg disease (EPM1): a population-wide Finnish study. Neurology 2015;84:1529-1536.
41. Martí-Massó JF, Bergareche A, Makarov V, et al. The ACMSD gene, involved in tryptophan metabolism, is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism. J Mol Med (Berl) 2013;91:1399-1406.
42. Wolf P, Yacubian EM, Avanzini G, Sander T, Schmitz B, Wandschneider B, Koepp M. Juvenile myoclonic epilepsy: a system disorder of the brain. Epilepsy Res 2015;114:2-12.
43. van Egmond ME, Verschuuren-Bemelmans CC, Nibbeling EA, et al. Ramsay Hunt syndrome: clinical characterization of progressive myoclonus ataxia caused by GOSR2 mutation. Mov Disord 2014;29:139-143.
44. Luciano AY, Jinnah HA, Pfeiffer RF, Truong DD, Nance MA, LeDoux MS. Treatment of myoclonus-dystonia syndrome with tetrabenazine. Parkinsonism Relat Disord 2014;20:1423-1426.
45. Roze E, Vidailhet M, Hubsch C, Navarro S, Grabli D. Pallidal stimulation for myoclonus-dystonia: ten years' outcome in two patients. Mov Disord 2015;30:871-872.
46. Starr PA. Deep brain stimulation for other tremors, myoclonus, and chorea. Handb Neurol 2013;116:209-215.
47. van der Salm SM, Erro R, Cordivari C, et al. Propriospinal myoclonus: clinical reappraisal and review of literature. Neurology 2014;83:1862-1870.
48. Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013;67:94-114.
49. Sinclair CF, Gurey LE, Blitzer A. Palatal myoclonus: algorithm for management with botulinum toxin based on clinical disease characteristics. Laryngoscope 2014;124:1164-1169.
50. Kern DS, Lang AE. Successful treatment of functional palatal tremor: insights into pathogenesis and management. Mov Disord 2015;30:875-876.
51. Sinha S, Sarin YK. Rituximab for opsoclonus myoclonus ataxia syndrome associated with neuroblastoma. Indian J Pediatr 2014;81:218-219.
52. Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 2013;28:543-547.
53. Baizabal-Carvallo JF, Jankovic J. Stiff-person syndrome: insights into a complex autoimmune disorder. J Neurol Neurosurg Psychiatry 2015;86:840-848.